Profiles:

Jia-Nian Chen, MD, associate professor. Jia-Nian Chen is currently employed by State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, and one of the teachers of School of Chemistry and Pharmacy. Research field: The synthesis, mechanisms, and druggability studies of molecular-targeted anti-cancer agents. He is expertised in molecular simulation and docking of lead compounds (organic small-molecular drugs). Over the past 5 years, receive funding of the National Natural Science Foundation of China (1 general program & 1 developing region program), Guangxi Natural Science Foundation of China (1 general program& 1 youth foundation), and other programs.Three of five National Patents for Invention were authorized. More than 10 scientific papers were published. Records of major academic experiences:

(1) In December, 2015, he was invited to be the Guest editor of the journal “Current Topics in Medicinal Chemistry”, a well-known journal in the field of medicinal chemistry. He organized two issues (27 and 28 of Volume 27) focusing on Multi-target Drug Discovery. A total of over 10 research groups from China, Canada, China and other countries were recruited, and 7 articles were selected and published finally. Please see the URL links: https://benthamscience.com/journals/current-topics-in-medicinal-chemistry/volume/17/issue/27/; https://benthamscience.com/journals/current-topics-in-medicinal-chemistry/volume/17/issue/28/. From sending invitation letters to contributions, to final publishment, the whole process was over two years, we did well. In May 2018, he was invited again and is currently collecting articles globally.

(2) In 2018, he was invited by Prof. Atta-ur-Rahman, FRS (chief editor of the journal “Current Medicinal Chemistry” and winner of the Friendship Award of Chinese government in 2014), and to be a Bentham brand ambassador in China.

(3) Manuscript reviewers: more than 10 journals including Current Medicinal Chemistry，Current Topics in Medicinal Chemistry，ChemMedChem，Mini-Reviews in Medicinal Chemistry，Bioorganic & Medicinal Chemistry Letters，Bioorganic Chemistry.

Education

2006/09–2011/06, College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, MD

2003/09–2006/06, College of Chemistry and Chemical Engineering, Hubei University, MSc

1999/09–2003/06, School of Food Science and Technology & School of Chemical Engineering, Hubei University of Arts and Science, BS

Career Profile

2013/12–Current, Associate Professor, State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (School of Chemistry and Pharmaceutical Sciences), Guangxi Normal University, Guilin, China

2011/08–2013/11, Lecturer, School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin, China

Representative Outcomes

1. Jia-Nian Chen*, Xian-Fu Wang, Ting Li, De-Wen Wu, Xiao-Bo Fu, Guang-Ji Zhang, Xing-Can Shen, Heng-Shan Wang. Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents. European Journal of Medicinal Chemistry, 2016, 107(1): 12–25. (TOP，IF=4.833. citations by others > 30 from web of science)

2. Jia-Nian Chen*, De-Wen Wu, Ting Li, Kang-Jian Yang, Li Cheng, Zu-Ping Zhou*, Shi-Ming Pu, Wan-Hua Lin. Arylurea derivatives: a class of potential cancer targeting agents. Current Topics in Medicinal Chemistry, 2017, 17(28): 3099–3130. (IF=3.442. Invited review,URL link (for free): https://pan.baidu.com/s/1nuJiUz3)

3. Xiao-Bo Fu, Xian-Fu Wang, Jia-Nian Chen*, De-Wen Wu, Ting Li, Xing-Can Shen, Jiang-Ke Qin. Synthesis, fluorescence properties, and antiproliferative potential of several 3-oxo-3H-benzo[f]chromene-2-carboxylic  acid derivatives. Molecules, 2015, 20(10): 18565–18584. (IF=3.06)

4. Jia-Nian Chen*. Editorial: Multi-target drug discovery – part II. Current Topics in Medicinal Chemistry, 2017, 17(28): 3081–3083. (IF=3.442)

5. Jia-Nian Chen*, Editorial: Multi-target drug discovery – part I. Current Topics in Medicinal Chemistry, 2017, 17(27): 2997–2999. (IF=3.442)

6. Jianian Chen, Shaoshun Li, Qi Shen*. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. European Journal of Pharmaceutical Sciences, 2012, 47(2): 430–443. (IF=3.532)

7. Jianian Chen, Shaoshun Li, Qi Shen*, Huijuan He, Yi Zhang. Enhanced cellular uptake of folic acid-conjugated PLGA–PEG nanoparticles loaded with vincristine sulfate in human breast cancer. Drug Development and Industrial Pharmacy, 2011, 37(11): 1339–1346. (IF=2.367)

8. Jianian Chen¹, Huijuan He¹, Shaoshun Li, Qi Shen*. An HPLC method for the pharmacokinetic study of vincristine sulfate-loaded PLGA–PEG nanoparticle formulations after injection to rats. Journal of chromatography B, Analytical Technologies in the Biomedical and Life Sciences, 2011, 879(21): 1967–1972. (IF=2.813)

9. 陈家念, 王先富, 张广吉, 傅晓波, 沈星灿, 吴德文, 李亭, 蒋邦平, 纪仕辰, 覃江克 黄春秋. 具有抗肿瘤作用的喹唑啉-芳基脲衍生物及其应用. 中国发明专利, ZL201410488594.5. 公告日2015-02-18. 授权日2016-06-29.

10. 陈家念, 傅晓波, 李亭, 沈星灿, 王先富, 吴德文, 蒋邦平, 纪仕辰, 覃江克, 刘冬成，黄春秋. 共载紫杉醇和增敏剂的纳米脂质体及其制备方法与应用. 中国发明专利, ZL201410595772.4. 公告日2015-03-11. 授权日2016-06-29

Research projects (State & Provincial and ministerial levels):

1. National Natural Science Foundation of China-general program, No: 21877019. Design, synthesis and anti-bladder cancer activities study of ferroptosis inducer based on Sxc-/GPx4/ROS biological axis, 2019/01-2022/12, 590 thousand RMB (under research).

2. National Natural Science Foundation of China-developing region program, No: 81860533. A bipyrazinylurea derivative reversing epirubicin resistance through ERK/Slug/vimentin/BCRP signal axis, 2019/01-2022/12, 348 thousand RMB (under research).

3. Guangxi Natural Science Foundation of China-general program, No: 2018GXNSFAA138109. The mechanism studies of induced ferroptosis and autophagy induced by quinazolinyl-diaryl urea derivatives in T24 and J82 bladder cancer cell lines, 2018/07–2021/07, 120 thousand RMB (under research).

4. Guangxi Natural Science Foundation of China-youth foundation, No: 2013GXNSFBA019200. The construction and drug delivery of paclitaxel-cyclodextrin inclusion complex PLGA nanoparticles, 2013/04–2016/03, 50 thousand RMB (completed study).

Group members

Graduate Students:

1. Tai-Sheng Qin, male, enrollment: September 2017. Major: Synthetic and Natural Medicinal Chemistry

2. Ye-Xiang Sun, female, enrollment: September 2018. Major: Pharmaceutical Engineering

3. Yue-Zhen He, female, enrollment: September 2019. Major: Synthetic and Natural Medicinal Chemistry

4. Chun-Ting Chen, female, enrollment: September 2019. Major: Synthetic and Natural Medicinal Chemistry

Postgraduates:

1. Guang-Ji Zhang, male, enrollment: September 2011; graduation: June 2014. Major: Organic chemistry. Present: Ph.D. candidates in Central South University (Changsha City)

2. Xiao-Bo Fu, female, enrollment: September 2012; graduation: June 2015. Major: Organic chemistry. Present: Zhejiang Normal University.

3. Xian-Fu Wang, male, enrollment: September 2013; graduation: June 2016. Major: Organic chemistry. Present: self-employment.

4. De-Wen Wu, male, enrollment: September 2014; graduation: June 2017. Major: Synthetic and Natural Medicinal Chemistry

5. Ting Li, female, enrollment: September 2014; graduation: June 2017. Major: Synthetic and Natural Medicinal Chemistry

6. Kang-Jiang Yang, male, enrollment: September 2015; graduation: June 2017. Major: Pharmaceutical Engineering

7. Li Cheng, female, enrollment: September 2016; graduation: June 2019. Major: Synthetic and Natural Medicinal Chemistry. Present: Ph.D. candidates in Xiangya Hospital of Central South University (Changsha City)